CSS
CEROW

Cubist Systematic Strategies’s CERo Therapeutics Warrants CEROW Stock Holding History

Cubist Systematic Strategies’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,500
Closed -$716 – 4189
2024
Q1 		$716 Sell
10,500
-6,240
-37% -$379 ﹤0.01% 3604
2023
Q4 		$393 Hold
16,740
– – ﹤0.01% 3488
2023
Q3 		$1.2K Hold
16,740
– – ﹤0.01% 3221
2023
Q2 		$1.02K Hold
16,740
– – ﹤0.01% 3366
2023
Q1 		$670 Hold
16,740
– – ﹤0.01% 3811
2022
Q4 		$721 Buy
+16,740
New +$881 ﹤0.01% 4159

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Cubist Systematic Strategies's CEROW Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of CERo Therapeutics Warrants (CEROW) in Q2 2024, closing a stake of 10,500 shares — an estimated $716 sold.

Cubist Systematic Strategies first reported a position in CEROW in Q4 2022 and held it in 6 quarters. The position peaked at $1.2K in Q3 2023. 34 funds tracked by Wall St. Rank hold CEROW as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining CERo Therapeutics Warrants position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,500 CERo Therapeutics Warrants shares in Q2 2024, an estimated $716.
  • Cubist Systematic Strategies first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 6 quarters.
  • Cubist Systematic Strategies's CERo Therapeutics Warrants position peaked at $1.2K in Q3 2023.
  • 34 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.